The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

Abstract Background In addition to morphological and cytogenetic features, acute myeloid leukemias are characterized by mutations that can be used for target-therapy; also the minimal/measurable residual disease (MRD) could be an important prognostic factor. The purpose of this retrospective study w...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Serena Salehzadeh, Francesca Guerrini, Umberto Pizzano, Susanna Grassi, Elena Ciabatti, Lorenzo Iovino, Gabriele Buda, Francesco Caracciolo, Edoardo Benedetti, Enrico Orciuolo, Matteo Pelosini, Giovanni Consani, Giovanni Carulli, Maria Rita Metelli, Francesca Martini, Francesco Mazziotta, Elisa Mazzantini, Pietro Rossi, Rita Tavarozzi, Federica Ricci, Mario Petrini, Sara Galimberti
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2019-04-01
Sarja:	Cancer Cell International
Aiheet:	AML FLT3 NPM1 WT1 ASXL1 TP53
Linkit:	http://link.springer.com/article/10.1186/s12935-019-0807-0
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!